The Technical Analyst
Atara Biotherapeutics Inc [ATRA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Atara Biotherapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-4.44% $0.661
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 78.90 mill |
| EPS: | -2.61 |
| P/E: | -0.250 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 119.36 mill |
| Avg Daily Volume: | 2.72 mill |
| RATING 2024-04-19 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.250 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -0.250 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.582 - 0.740 ( +/- 11.95%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-31 | Fust Matthew K | Buy | 150 000 | Common Stock |
| 2024-03-31 | Heiden William K | Buy | 150 000 | Common Stock |
| 2024-03-31 | Roncarolo Maria Grazia | Buy | 150 000 | Common Stock |
| 2024-03-31 | Gallagher Carol Giltner | Buy | 150 000 | Common Stock |
| 2024-03-31 | Mallik Ameet | Buy | 150 000 | Common Stock |
| INSIDER POWER |
|---|
| 70.15 |
| Last 100 transactions |
| Buy: 8 350 944 | Sell: 2 074 393 |
Forecast:
16:00 - $0.672
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.672
Forecast 2: 16:00 - $0.672
Forecast 3: 16:00 - $0.672
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.661 (-4.44% ) |
| Volume | 1.619 mill |
| Avg. Vol. | 2.72 mill |
| % of Avg. Vol | 59.47 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ATRA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $0.800 | N/A | Active |
|---|
ATRA
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-04-05 16:01:00 - Press Release
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of atara's common stock to one newly hired employee. this award was approved by the compensation committee of atara's board of directors and granted under the atara.
2024-03-28 08:30:00 - Press Release
Atara Biotherapeutics Announces Fourth Quarter And Full Year 2023 Financial Results And Operational Progress
Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2023, recent business highlights, and key upcoming milestones for 2024. “we are expanding atara's proven ebv t-cell platform into allogeneic car t thera.
2024-02-29 09:05:00 - Press Release
Atara Biotherapeutics Receives Fda Clearance Of Ind Application In Lupus Nephritis For Ata3219, An Allogeneic Car T Therapy
Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the u.s. food and drug administration (fda) has cleared an investigational new drug (ind) application for ata3219, an allogeneic, anti-cd19 chimeric antigen receptor (car) t-cell monotherapy for the treatme.
2024-02-28 16:30:00 - Press Release
Atara Biotherapeutics To Participate In Cell Therapy Panel Discussion At The Cowen 44th Annual Health Care Conference
Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that pascal touchon, president and chief executive officer, will participate in a cell therapy panel discussion at the cowen 44th annual health care conference on wednesday, march 6, 2024 at 6:10 a.m. pst /.
2024-02-14 09:00:00 - Press Release
Atara Biotherapeutics Announces Submission Of Investigational New Drug Application For Ata3219 For Treatment Of Lupus Nephritis
Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an investigational new drug (ind) application to the u.s. food and drug administration (fda) for the use of ata3219 as a monotherapy for the treatment of systemic lupus erythematosu.
Latest News
2024-03-28 10:41:17 - Zacks Investment Research
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.72 per share a year ago.
2024-02-05 19:24:23 - Seeking Alpha
Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease. The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway.
2024-01-04 16:01:00 - Business Wire
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, at 9:45 a.m. PST / 12:45 p.m. EST in San Francisco, Cal.
2023-11-29 18:05:00 - Business Wire
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced positive new data for tabelecleucel (tab-cel® or EBVALLO™) in patients with relapsed or refractory (r/r) or treatment-naïve Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving.
2023-11-22 15:14:10 - PennyStocks
Penny Stocks To Buy Under $1? 3 For Your Holiday Watch List
Penny stocks offer investors the chance to get in on the ground floor of small companies with growth potential. They also offer high-volatility trading opportunities daily that can see huge moves of 100% or more.
2023-11-17 13:32:10 - PennyStocks
11 Top Penny Stocks To Buy Now According To Insiders
Ever wonder what signals to look for in the stock market today? Let's talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch.
2023-11-15 12:52:53 - PennyStocks
5 Penny Stocks To Buy Now According To Insiders
Penny stocks are often priced under $5 per share. They attract traders seeking big gains.
2023-11-13 02:13:54 - Seeking Alpha
Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity
Atara Biotherapeutics stock price dropped by 80% following failure of ATA188 in a phase 2 study in multiple sclerosis. This was an excessive reaction by the market in my opinion. ATRA's restructuring, tab-cel deal with Pierre Fabre, and lower future R&D expenses (considering failure of ATA188 and prioritization of ATA3219 and ATA3431) have extended cash runaway beyond Q3 2025. Pierre Fabre will not only take over all costs associated with tab-cel but will also pay ATRA $30M upfront, as well as $100M in regulatory milestone payments through BLA approval.
2023-11-04 11:45:28 - Seeking Alpha
Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript
Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2023 Results Conference Call November 1, 2023 9:00 AM ET Company Participants Alex Chapman - VP, Corporate Communications & IR Dr. Pascal Touchon - President and CEO Eric Hyllengren - CFO Conference Call Participants Salim Syed - Mizuho John Newman - Canaccord Genuity Phil Nadeau - Cowen & Company Jonathan Miller - Evercore ISI Tommie Reerink - Goldman Sachs Operator Good morning, and thank you for standing by. Welcome to Atara Biotherapeutics' Third Quarter 2023 Financial Results Conference Call.
2023-09-21 10:31:21 - Zacks Investment Research
Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study
Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.